Table 1.
The list of primers used to study the expression profile of the indicated gene.
Fig 1.
Expression of SFRP4 in A) Breast invasive carcinoma B) Main subtypes of breast cancer C) Individual D) with tumour and normal samples and, E) The Kaplan-Meier survival analysis and enrichment analysis of SFRP4 with, F) GO and G) KEGG biological process graph.
Fig 2.
3D structure of the SFRP4.
Table 2.
Evaluation of the two most effective drugs using the parameters supplied by the computational prediction approach for drug likeness.
Table 3.
Molecular docking energy values of SFRP4 with candidate compounds.
Fig 3.
Predicted binding conformation of Silibinin and Isotretinoin with the designated ligand-binding site of sFRP4.
A, B Interfaces are produced through the participation of protein-ligand complexes.
Fig 4.
Simulation results in A, A՛: Protein RMSD and RMSF for Silibinin complex.
Fig 5.
Simulation results in (B, B՛): Protein RMSD and RMSF for Isotretinoin complex.
Fig 6.
Simulation interaction diagram of silibinin (A, A՛) 2-D interactions illustration of the protein–Ligand.
Fig 7.
Simulation interaction diagram of isotretinoin (B, B՛) 2-D interactions illustration of the protein–Ligand.
Fig 8.
Anti-proliferative activity of Silibinin and isotretinoin in a dose-dependent manner by MTT assay.
Fig 9.
Silibinin and isotretinoin (A, B) stop MDA-MB-231 cells from migrating.
Means ± SD of three separate experiments provide the data reported in A and B. **P < 0.01 in comparison to the control cohort.
Fig 10.
The expression of sFRP4 in TNBC MDA-MB-231 cell lines after treatment with silibinin and isotretinoin and its subsequent effects.
The cells were subjected to a range of doses of silibinin and isotretinoin, ranging from 12.5 to 50 μM, for 48 hours. The findings of these investigations are presented as the means ± standard error of the mean (SEM) from three separate experiments. Statistical significance was assessed in Figures A and B. Effect of Silibinin and Isotretinoin affects the mRNA expression of the Wnt/β-catenin antagonist sFRP4 following 48 hours of exposure. Comparatively to untreated controls, both compounds affect the expression of sFRP4 gene in Figure C (**P < 0.05, ***P < 0.001).